RxDoctor Payments DataLook up a doctor →

Gerald Sacks, MD

Pain Medicine · Santa Monica, CANPI 1205906781

Payments from drug & device makers

$388,543in general payments, 2019–2025

Across 1,223 payments — averaging $317.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$149K
  • Scilex Pharmaceuticals Inc.$102K
  • Biohaven Pharmaceuticals, Inc.$70K
  • MDD US Operations, LLC$16K
  • West Therapeutics Development, LLC$15K
  • IBSA Pharma Inc.$11K
  • plus $26K from 37 others

What the payments were for

  • Consulting fees$48,20012%
  • Speaking & faculty fees$287,91174%
  • Travel & lodging$28,7637%
  • Food & beverage$23,6626%
  • Education$60%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$388,543 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$534,779
Medicare patients
222
Services billed
4,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine20$22,411
Levorphanol Tartrate13$8,955
NucyntaTapentadol Hcl13$8,557
Gabapentin ErGabapentin19$5,711
Duloxetine Hcl259$3,985
Gabapentin379$3,902
Celecoxib129$2,422
Lidocaine15$1,923
Naloxone Hcl21$1,345
Pregabalin50$767
Oxycodone Hcl42$548
Methocarbamol57$541
Nortriptyline Hcl60$521
Cyclobenzaprine Hcl49$386
Baclofen12$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$101,696$22,41120 claims
Virtus Pharmaceuticals LLCLevorphanol Tartrate$135$8,95513 claims
Collegium Pharmaceutical, Inc.Nucynta$746$8,55713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.

Other pain medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →